{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T13:03:09Z","timestamp":1748178189367},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00393-020-00853-9","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T15:03:50Z","timestamp":1597935830000},"page":"1046-1049","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Erfolgreiche Behandlung eines adulten Morbus Still mit Tofacitinib bei einer HIV-2-positiven Patientin"],"prefix":"10.1007","volume":"79","author":[{"given":"P.","family":"Hoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Walther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wesselmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Weinerth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Feist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ohrndorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"2","key":"853_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter\u00a0JI et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124\u2013131","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"853_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist\u00a0E, Mitrovic\u00a0S, Fautrel\u00a0B (2018) Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol 14(10):603\u2013618","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"853_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13075-019-2021-9","volume":"21","author":"S Colafrancesco","year":"2019","unstructured":"Colafrancesco\u00a0S et al (2019) Management of adult-onset Still\u2019s disease with interleukin\u20111 inhibitors: evidence- and consensus-based statements by a\u00a0panel of Italian experts. Arthritis Res Ther 21(1):275","journal-title":"Arthritis Res Ther"},{"key":"853_CR4","volume-title":"HIV-1 associated opportunistic infections","author":"AA Justiz Vaillant","year":"2020","unstructured":"Justiz Vaillant\u00a0AA, Naik\u00a0R (2020) HIV\u20111 associated opportunistic infections. StatPearls, Treasure Island"},{"issue":"3","key":"853_CR5","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi\u00a0M et\u00a0al (1992) Preliminary criteria for classification of adult Still\u2019s disease. J\u00a0Rheumatol 19(3):424\u2013430","journal-title":"J Rheumatol"},{"issue":"6","key":"853_CR6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","volume":"79","author":"Q Hu","year":"2020","unstructured":"Hu\u00a0Q et al (2020) Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a\u00a0single centre in China. Ann Rheum Dis 79(6):842\u2013844","journal-title":"Ann Rheum Dis"},{"key":"853_CR7","first-page":"1","volume":"p","author":"M Honda","year":"2020","unstructured":"Honda\u00a0M et al (2020) Tofacitinib-induced remission in refractory adult-onset Still\u2019s disease complicated by macrophage activation syndrome. Scand J Rheumatol p:1\u20133","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"853_CR8","doi-asserted-by":"publisher","first-page":"e20182845","DOI":"10.1542\/peds.2018-2845","volume":"143","author":"Z Huang","year":"2019","unstructured":"Huang\u00a0Z et\u00a0al (2019) Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics 143(5):e20182845","journal-title":"Pediatrics"},{"issue":"1","key":"853_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt\u00a0J et al (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a\u00a0global, open-label, long-term extension study. Arthritis Res Ther 21(1):89","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"853_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00393-020-00768-5","volume":"79","author":"R Alten","year":"2020","unstructured":"Alten\u00a0R et\u00a0al (2020) Janus kinase inhibitors : state of the art in clinical use and future perspectives. Z\u00a0Rheumatol 79(3):241\u2013254","journal-title":"Z Rheumatol"},{"issue":"1","key":"853_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes\u00a0IB et\u00a0al (2019) Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther 21(1):183","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"853_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-018-1685-x","volume":"20","author":"MY Furuya","year":"2018","unstructured":"Furuya\u00a0MY et al (2018) Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. Arthritis Res Ther 20(1):196","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"853_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1164\/rccm.201903-0659OC","volume":"201","author":"E Verweyen","year":"2020","unstructured":"Verweyen\u00a0E et al (2020) Synergistic signaling of TLR and IFNalpha\/beta facilitates escape of IL-18 expression from endotoxin tolerance. Am J Respir Crit Care Med 201(5):526\u2013539","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"853_CR14","first-page":"840","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay\u00a0C et al (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis 77(6):840\u2013847","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"853_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","volume":"17","author":"C Le Berre","year":"2019","unstructured":"Le Berre\u00a0C, Loeuille\u00a0D, Peyrin-Biroulet\u00a0L (2019) Combination therapy with vedolizumab and tofacitinib in a\u00a0patient with ulcerative colitis and spondyloarthropathy. Clin Gastroenterol Hepatol 17(4):794\u2013796","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"853_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/RHU.0000000000000663","volume":"24","author":"NS Barroso","year":"2018","unstructured":"Barroso\u00a0NS, Miller\u00a0EZ, Furst\u00a0DE (2018) A case series on patients on tofacitinib in combination with a\u00a0biologic. J\u00a0Clin Rheumatol 24(6):349\u2013351","journal-title":"J Clin Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00853-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00853-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00853-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:49:49Z","timestamp":1629416989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00853-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00853-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"20 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Hoff ist als Referentin f\u00fcr die Firma Pfizer und Novartis t\u00e4tig und erhielt Forschungsf\u00f6rderung der Firma Pfizer. E.\u00a0Feist ist als Referent f\u00fcr Novartis, Sobi und Pfizer t\u00e4tig. J.\u00a0Weinerth ist als Referentin f\u00fcr die Firma Novartis t\u00e4tig. S.\u00a0Ohrndorf ist als Referentin f\u00fcr die Firma Novartis t\u00e4tig und erh\u00e4lt Forschungsf\u00f6rderung der Firma Novartis. H.\u00a0Wesselmann ist als Referent f\u00fcr die Firmen MSD, ViiV, BMS t\u00e4tig. M.\u00a0Walther gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}